Highlights from ESMO 2024

In this week’s podcast, we bring you updates from the ESMO 2024 Congress in Barcelona, featuring expert discussions on cutting-edge oncology research. We are joined by Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK; Minke Lukas, MD, Netherlands Cancer Institute, Amsterdam; Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL; Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden Hospital, London; Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Italy; and Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany. We’ll hear about final overall survival results from the Phase II KEYNOTE-522 trial (NCT03036488) of pembrolizumab in triple-negative breast cancer, updates from the Phase III NADINA trial (NCT04949113) of ipilimumab and nivolumab in melanoma, and findings from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in urothelial carcinoma, as well as the Phase III NIAGARA trial (NCT03732677) of neoadjuvant immunotherapy in muscle-invasive bladder cancer. Other highlights include data from the Phase III MARIPOSA-2 trial (NCT04487080) of amivantamab in EGFR-mutant lung cancer, the Phase III KEYNOTE-A18 (NCT04221945) study in cervical cancer, and the Phase III POD1UM-303 trial (NCT04472429) of retifanlimab in squamous cell anal carcinoma. Subscribe to our podcast on Apple Podcasts, Podbean, and Spotify, and join the conversation on X (formerly Twitter) @VJOncology. For more exclusive content on ESMO 2024, visit vjoncology.com.